49 results about "Immune dysregulation" patented technology

This disclosure relates to recombinant immunoglobulin endoglycosidases and uses in managing diseases or conditions associated with immune dysregulation or inflammation. In certain embodiments, the recombinant immunoglobulin endoglycosidases comprise sequences disclosed herein. In certain embodiments, this disclosure relates to pharmaceutical compositions and methods of treating or preventing an autoimmune disease or inflammatory condition comprising administering to a subject in need thereof an effective amount of a recombinant immunoglobulin endoglycosidase, or nucleic acids or vector encoding the same, as disclosed herein.

The invention belongs to the technical field of fish disease prevention and treatment, and particularly relates to application of chlorogenic acid in preparation of a product for preventing and treating GCHV viral inflammation. The regulation and control effects of chlorogenic acids with different concentrations (0.1%, 0.5% and 1%) on inflammatory factors (TNF-alpha, IL-1beta and IL-16) infected by the GCRV II virus are systematically analyzed, and the condition that the expression of the inflammatory factors (TNF-alpha, IL-1beta and IL-16) is obviously inhibited from the third day to the seventh day after infection by 0.5% chlorogenic acid is found; 0.01), the effect of which is not statistically different from that of the blank group (CK) (pgt; 0.05) of the method. If the high-concentration group has proinflammatory effect inversion (IL-1beta superscript 15.4%, p = 0.031) on the ninth day, dose-dependent toxicity is prompted. Results show that 0.5% chlorogenic acid can effectively inhibit viral inflammatory response, and long-term use of high dosage of chlorogenic acid may cause immune disorder.

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

This invention discloses a class of pyrazolopyridine compounds linked by an aza-four-membered ring, or pharmaceutically acceptable salts thereof, and their applications. These compounds can serve as novel, highly selective PDE10A inhibitors for the treatment of peripheral tissue diseases, including: myocardial hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal impairment and renal fibrosis, pulmonary inflammation and pulmonary fibrosis, immune dysregulation, and cancers (colon cancer, ovarian cancer, and lung cancer). Two strategies are employed to achieve high selectivity for PDE10A inhibition while simultaneously reducing the inhibitory effect on the central nervous system. First, molecular structure modification: structural optimization of the aza-four-membered ring-linked pyrazolopyridine compounds, such as increasing the ratio of N, O, and S atoms in the molecular structure to increase the polar surface area and reduce lipophilicity; and introducing hydrophilic groups to increase water solubility, thereby reducing the permeability of the compound to the blood-brain barrier (BBB). Second, targeted drug delivery to lung tissue via pharmaceutical formulation.

The invention provides an anti-CXCR6 antibody and an application thereof. The anti-CXCR6 antibody provided by the invention can bind to CXCR6 with high affinity and high specificity, has species cross binding activity of human and monkey CXCR6, and is a CXCR6-targeted clearance antibody, so that the anti-CXCR6 antibody has great potential to be used for treating inflammation or immune disorder diseases; moreover, compared with the existing CXCR6 antibody, the anti-CXCR6 antibody provided by the invention has obviously lower cell nonspecific binding, so that the anti-CXCR6 antibody provided by the invention has lower off-target toxicity and better safety.

The invention relates to a gene-edited cytotoxic cell comprising a chimeric antigen receptor (CAR) that binds CD30, for use in the treatment of an infection, in which infected cells express CD30. In embodiments, the treatment comprises the cytotoxic cell binding to a human target cell, which is infected with a chronic inflammatory virus and expresses CD30. In embodiments, the treatment comprises cytotoxic activity against a reservoir of infected human CD30-expressing target cells in a subject with a chronic viral infection with associated pathologies, immune dysregulations and autoimmune diseases. Corresponding medical uses and methods of treatment are encompassed by the present invention. In another aspect, the invention relates to the CD30-CAR-expressing gene-edited cytotoxic cell as described herein. In other aspects, the invention relates to the CD30-CAR nucleic acid construct and the CAR polypeptide as described herein.

The present invention relates to a second generation vaccine against COVID-19 to eliminate or reduce the binding of the SARS-CoV-2 spike (S) protein or parts thereof to human angiotensin-converting enzyme 2 (hACE2). Such vaccines have several advantages to avoid immune dysregulation pathways activated after the S protein / hACE2 interaction, while maintaining the ability to elicit a strong and robust antibody neutralization response against SARS-CoV-2. The present invention also relates to the use of the S protein for therapeutic use and for vaccines in the prevention or treatment of SARS-CoV-2 infection or a disease or disorder caused by such infection.

The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein / hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.

Embodiments of the invention include the use of flavonoids to modulate inflammation of the CNS. Formulations and methods described herein can treat traumatic brain injuries (TBI) and Alzheimer's disease (AD) by reducing systematic inflammation and modulating immune dysregulation. The formulations and methods include antagonists that bind to receptors (CCR2 and GPR55) and a prostaglandin (PGE2). When administered therapeutically with 17-DHA and / or THEA, their combined activity can reduce systemic inflammation and post-trauma inflammation. In aspects, one or more of the compounds work synergistically with one another.

The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein / hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.

The invention relates to the technical field of molecular biology, in particular to application of RIPK3 gene mutation as a detection target and a detection reagent. An experiment shows that an individual with heterozygote RIPK3 mutation (c.400Cgt; A, p.Gln134Lys) shows the symptom of a Still disease sample self-inflammatory disease, and a potential relation exists between the variation and immune disorder, and is characterized in that necroptosis sensitivity is increased and an inflammatory signal is amplified, so that a pro-inflammatory environment is caused. According to the invention, the relation between RIPK3 variation and the expression of the self-inflammatory disease of the Stetier disease sample is established, the understanding of people on the molecular basis of the self-inflammatory disease of the Stetier disease sample is expanded, and the importance of RIPK3 in human immune homeostasis is emphasized.

The invention provides an application of a melanoma-derived exosome in a medicine for preventing and treating corneal transplantation immunological rejection, belongs to the technical field of ophthalmology biological medicines, and adopts a mouse corneal transplantation model to find that B16-Exo can inhibit immunological rejection, which is represented by corneal opacity, neovascularization, alleviation of immune disorder and improvement of postoperative survival rate. Proteome analysis reveals differential expression of key protein in B16-Exo, especially JAK2 protein in a JAK-STAT signal channel, further mechanism research clarifies the effect of the JAK2 protein in enhancement of myeloid-derived suppressor cell activity and inhibition of T cell proliferation, and these findings prove that B16-Exo has a remarkable immunoregulation effect in transplantation immunology, and can be used for preparing a medicine for treating myeloid-derived suppressor cell activity and T cell proliferation. And a basis is provided for further exploring the tumor cell exosome as an effective therapeutic agent for managing immunological rejection in organ transplantation.

The invention provides a derivative of an impatiens balsamina plant extract 2-methoxy-1, 4-naphthoquinone and an application of the derivative in preparation of an anti-inflammatory drug. Belongs to the technical field of chemical pharmacy. The derivative of 2-methoxy-1, 4-naphthoquinone provided by the invention has a good treatment effect on inflammation, and due to the fact that the derivative of 2-methoxy-1, 4-naphthoquinone is a plant active component, immune disorder, adverse reaction and drug resistance caused by traditional drugs can be avoided. And compared with 2-methoxy-1, 4 naphthoquinone, the 2-methoxy-1, 4 naphthoquinone has the advantages of lower cytotoxicity and higher safety.

The present disclosure provides anti-TIGIT polypeptides or fragments thereof. Further provided are methods of using the antibodies or fragments thereof for the treatment and diagnosis of diseases, such as cancer, infection, or immune disorders.

Provided are humanized monoclonal antibodies targeting CD38 for use in treating immune thrombocytopenia (ITP). The anti-CD38 monoclonal antibodies stand out by their unique mechanism of action, which includes reducing autoantibody-mediated platelet destruction and modulating the immune system, thereby restoring hemostatic balance, which addresses both the symptoms of ITP and the underlying immune dysregulation features.

The invention relates to the technical field of medicines, and provides a CMHs nano-enzyme as well as a preparation method and an application method thereof. The CMHs nano enzyme sequentially comprises CORM-401, a halloysite nano tube and a manganese oxide nano enzyme from inside to outside; wherein the manganese oxide nano-enzyme is generated on the surface of the halloysite nanotube through an in-situ reaction, and the carbon monoxide release molecules can release carbon monoxide. The CMHs nano-enzyme disclosed by the invention is combined with the manganese oxide nano-enzyme, the halloysite nanotube and the carbon monoxide release molecules, so that the inflammatory bowel disease is effectively treated through multiple synergistic effects; the halloysite nanotube provides a targeted delivery function, the manganese oxide nano enzyme has an anti-oxidation effect, and the carbon monoxide can further enhance the anti-oxidation effect, inhibit inflammatory reaction and relieve inflammatory related pain at the same time; the three components are matched with one another, so that the anti-oxidation and anti-inflammatory effects are enhanced, the intestinal repair can be promoted, the oxidative stress and immune disorder of a focus area are relieved, and meanwhile, the chronic pain related to the inflammatory bowel disease is effectively relieved.

The invention discloses application of a monoclonal antibody 2F5 in autoimmune diseases and regulation and control of B cells, the monoclonal antibody 2F5 is obtained from SLE peripheral blood, and it is proved for the first time that the monoclonal antibody 2F5 can promote proliferation, activation and differentiation of the B cells through primary cell and cell line experimental models. The antibody provided by the invention is completely humanized and clear in targeting, can well simulate the blood microenvironment of the high-titer autoantibody in the peripheral blood of an autoimmune disease patient, is an ideal tool for defining the biological function of the autoantibody and researching the regulation and control of the autoantibody on the activation and differentiation of B cells, is beneficial to deepening the understanding of a mechanism causing immune disorder, and has a good application prospect. Therefore, the treatment intervention of immune pathological diseases caused by abnormal differentiation of B cells becomes possible, and an important foundation is laid for developing a new target spot of targeted pathogenic B cells for treating autoimmune diseases and tumors.

Provided are a plurality of CpG-containing oligodeoxynucleotides (ODNs) capable of regulating the immune function of the body and the use thereof. The design concept of the sequences and structures of the oligodeoxynucleotides are different from those of a traditional type-A CpG ODN, which embodies the complex druggability rules of the oligodeoxynucleotides, and solves the druggability problem of the traditional type-A CpG. The oligodeoxynucleotides have the activity of regulating the immune function of the body both in vitro and in vivo, can stimulate the production of type I, II and III interferons, up-regulate a Th1-type immune response, and suppress Th2-type and Th17-type inflammatory responses. Therefore, the oligodeoxynucleotides can be used in the prevention and treatment of allergic diseases, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary diseases, and diseases associated with eosinophilic granulocytes and Th17, caused by a Th2-type immune response; can be used in the prevention and treatment of the infection and transmission of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites; can be used to improve the immunity level of the elderly population and people with immunodeficiency; can be used to convert "cold tumors" into "hot tumors" and improve the effect of cancer immunotherapy; can be used in the prevention and treatment of central nervous system diseases associated with immune dysfunction such as Alzheimer's disease; and can be used for other diseases associated with immune dysfunction.

This invention provides multiple oligodeoxyribonucleotides (ODNs), including CpGs, that have the function of modulating the immune system of organisms, and their uses. These oligodeoxyribonucleotides differ in sequence and structure from the design concepts of conventional type A CpG ODNs, demonstrating complex drug discovery rules and solving the challenges of conventional type A CpG drug discovery. They exhibit excellent activity in modulating the immune function of organisms both in vitro and in vivo, stimulating the production of type I, II, and III interferons, enhancing the Th1 immune response, and suppressing Th2 and Th17 inflammatory responses. Therefore, they can prevent and treat allergic diseases caused by Th2 immune responses, such as allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic granulocyte and Th17-related diseases, prevent and treat infection and transmission of respiratory or non-respiratory pathogenic microorganisms such as viruses, bacteria, fungi, and parasites, and improve immune levels in elderly and immunocompromised populations. It can transform "cold tumors" into "hot tumors," improve the effectiveness of cancer immunotherapy, prevent and treat central nervous system diseases associated with immune dysregulation such as Alzheimer's disease, and can also be used for other diseases associated with immune dysregulation.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.

Compounds of formula (I) and formula (II) capable of binding to Granzyme B. Also provided herein are pharmaceutical compositions comprising such compounds, e.g., for use in imaging Granzyme B and / or treating immune dysregulation.

The present application belongs to the field of food, and particularly relates to a nutritional composition and its use for improving immune disorders, more particularly to the use of a nutritional composition in the preparation of a food for improving the level disorder of inflammatory factors in offspring caused by maternal immune activation; the nutritional composition comprises essential active ingredients shown as (i) and (ii): (i) neutral fucosylated human milk oligosaccharides, (ii) neutral non-fucosylated human milk oligosaccharides; wherein the neutral fucosylated human milk oligosaccharides at least comprise 2'-fucosyllactose, and the neutral non-fucosylated human milk oligosaccharides at least comprise lacto-N-neotetraose; and in the nutritional composition, the mass ratio of the lacto-N-neotetraose to the 2'-fucosyllactose is 1:(1-8). 2'-fucosyllactose and lacto-N-neotetraose can synergistically regulate offspring immunity.

The invention discloses a Yifang polypeptide composition as well as a preparation method and application thereof, and belongs to the technical field of compositions. The beneficial formula polypeptide composition comprises a probiotic mixture, a prebiotic mixture and a polypeptide mixture. The composition capable of achieving a multi-target synergistic effect is constructed by scientifically compounding probiotics, prebiotics and various active polypeptides, so that the intestinal flora balance can be adjusted, the release of inflammatory factors can be inhibited through the biological activity of the polypeptides, the intestinal barrier function is repaired, and the intestinal health is improved. Therefore, the problems of gastrointestinal dysfunction, skin symptoms, immune disorder and the like caused by intestinal problems are fundamentally improved, and a more comprehensive and efficient solution is provided for solving complex intestinal health problems.

This invention discloses an 8–18 nm covalently bonded pH-responsive biomass active pharmaceutical ingredient (API), its preparation method, and its applications. The API has a three-layer covalently bonded core-shell structure, is free of free small molecules, and exhibits excellent structural stability. It is prepared from bamboo-derived biomass raw materials such as modified bile acid-bamboo flavonoid cocrystal complex, modified bamboo polysaccharides, and galactose oligosaccharides. The product has a particle size of 8–18 nm, a PDI < 0.21, a Zeta potential of -8.0 to -11.0 mV, and possesses pH-targeted drug release characteristics within the renal lesion microenvironment. Under normal physiological conditions, the drug leakage rate is less than 3.2%, and the in vivo biodegradation rate exceeds 99.1% within 72 hours. It exhibits no tissue accumulation and high safety. This invention targets the common pathological features of renal oxidative stress, chronic inflammation, and immune dysregulation in viral renal failure and renal cancer, exerting therapeutic effects through antioxidant, anti-inflammatory, renal tubular barrier repair, and immune regulation mechanisms. This invention employs a room-temperature pure aqueous phase reaction combined with a two-stage ultrafiltration process, ensuring mild conditions, batch stability, and suitability for industrial mass production.

The present invention discloses a strain of Lactobacillus reuteri WLRE03 producing ergothioneine and its microbial agent and application, belonging to the field of microbial technology. The strain was deposited in the China Center for Type Culture Collection on December 8, 2023, with the deposit address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M 20232504. (1) The present invention provides a strain of Lactobacillus reuteri WLRE03 with high ergothioneine production, which is isolated from healthy poultry excrement and has the ability to produce ergothioneine; (2) Ergothioneine can alleviate intestinal barrier damage, dysbacteriosis and immune disorders caused by oxidative stress; (3) The ergothioneine production method provided by the present invention has the characteristics of simple operation, easy acquisition, low cost and suitability for industrial production, and can be used as a natural antioxidant in the food industry.

The present invention relates to methods of treating lentivirus and other viral infections. Viral zinc finger domains are considered critical targets across multiple virus families, as they are highly mutationally restricted and serve critical roles in both virus replication and in virus-host interactions, which are the sabotaging interactions that can cause complications of inflammation and immune dysregulation. Human immunodeficiency virus mutates faster than any other known virus, establishing precedence for other potential virus infection indications.

The application discloses application of monoclonal antibody 2F5 in autoimmune diseases and regulation of B cells, wherein the monoclonal antibody 2F5 is obtained from peripheral blood of SLE, and it is first proved that the monoclonal antibody 2F5 can promote B cell proliferation, activation and differentiation through primary cell and cell line experiment models. The antibody provided by the application is completely humanized, has clear targeting, can well simulate a blood microenvironment of high-titer autoantibodies in peripheral blood of an autoimmune disease patient, is an ideal tool for understanding biological functions of the autoantibodies and studying regulation of B cell activation and differentiation by the autoantibodies, and is helpful to deepen understanding of mechanisms of immune disorders, to make it possible to treat immunopathological diseases caused by abnormal differentiation of B cells, and to lay an important foundation for developing a new target for treating autoimmune diseases and tumors by targeting pathogenic B cells.

The present application relates to the use of pyrazolopyrimidine compounds of general formula (I). The compounds are effective in inhibiting the activity of CD73 and have good application prospects as CD73 small molecule inhibitors in the treatment and / or prevention of CD73-related diseases, disorders and conditions, particularly cancer and immune disorders.